Ependymoma
75
17
29
23
Key Insights
Highlights
Success Rate
68% trial completion
Published Results
17 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
14.7%
11 terminated out of 75 trials
67.6%
-18.9% vs benchmark
1%
1 trials in Phase 3/4
74%
17 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 23 completed trials
Clinical Trials (75)
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
Rare CNS Tumors Outcomes &Risk
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
B7-H3.CD28Z.CART in CNS Neoplasms
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Social Determinants of Health in Glioblastoma Population
AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Selumetinib for NF2-Related Schwannomatosis
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Methionine PET/CT Studies In Patients With Cancer
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).